VADUZ, LIECHTENSTEIN, Jan. 13 /PRNewswire/ - Helix BioPharma Corp. proposes to raise $32 million in its current fiscal year through the issuance of common shares and warrants ($25 million in its propose private placement and $7 million already raised in October, 2006). The result is that the shareholders of Helix could be diluted by up to 107% at a price as low as $1.80 per share.
